Pelthos Therapeutics Inc.
StreetZero Signal 70
About Pelthos Therapeutics Inc.
Pelthos Therapeutics Inc. is a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs. Its lead product ZELSUVMI is the first and only FDA-approved prescription medication for Molluscum contagiosum that can be administered at home. The company also plans to launch Xepi and Xeglyze. Headquartered in Durham, NC, it was founded in 2024 and operates as a privately held B2B pharmaceutical manufacturer.
LATEST FUNDINGPrivate Placement
$57.5M
Announced 2026-11-16
TOTAL RAISED$98M
IN THE NEWS
- ๐ Pelthos Therapeutics Secures Up to $50 Million Senior Secured Term Loan Facility from Horizon Technology Finance - Pelthos Therapeutics
- ๐ Pelthos Therapeutics
- ๐ Ligand Pharmaceuticals Incorporated - Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics
- ๐ [PDF] 11/13/2025 - Pelthos Therapeutics Inc.
- ๐ Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics
EMPLOYEESโ
FOUNDED2024
HQDurham, NC, United States
Industry
Pharmaceuticals
Tags
PharmaceuticalsBiopharmaceuticalTherapeutics
Key highlights
- Secured up to $50M senior secured term loan facility from Horizon Technology Finance with $30M initially funded.
- Completed merger with Channel Therapeutics supported by $50M equity raise led by Murchinson.
- Commercializing ZELSUVMI, the first at-home prescription treatment for Molluscum contagiosum.
- Ligand Pharmaceuticals entitled to 13% royalty on worldwide ZELSUVMI sales.
- Total funding reached $98M across three rounds including Post-IPO debt.
Ask StreetZero about Pelthos Therapeutics Inc.
Put our AI to work on this deal.
Similar companies
Other Pharmaceuticals deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account